These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Conversion from high-dose full-opioid agonists to sublingual buprenorphine reduces pain scores and improves quality of life for chronic pain patients. Daitch D; Daitch J; Novinson D; Frey M; Mitnick C; Pergolizzi J Pain Med; 2014 Dec; 15(12):2087-94. PubMed ID: 25220043 [TBL] [Abstract][Full Text] [Related]
3. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626 [TBL] [Abstract][Full Text] [Related]
4. Transdermal buprenorphine in the treatment of chronic pain: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. Sorge J; Sittl R Clin Ther; 2004 Nov; 26(11):1808-20. PubMed ID: 15639693 [TBL] [Abstract][Full Text] [Related]
5. Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: results of a retrospective cohort study. Sittl R; Likar R; Nautrup BP Clin Ther; 2005 Feb; 27(2):225-37. PubMed ID: 15811486 [TBL] [Abstract][Full Text] [Related]
6. Opioid addicts at admission vs. slow-release oral morphine, methadone, and sublingual buprenorphine maintenance treatment participants. Giacomuzzi S; Kemmler G; Ertl M; Riemer Y Subst Use Misuse; 2006; 41(2):223-44. PubMed ID: 16393744 [TBL] [Abstract][Full Text] [Related]
7. Effects of intravenous patient-controlled analgesia with buprenorphine and morphine alone and in combination during the first 12 postoperative hours: a randomized, double-blind, four-arm trial in adults undergoing abdominal surgery. Oifa S; Sydoruk T; White I; Ekstein MP; Marouani N; Chazan S; Skornick Y; Weinbroum AA Clin Ther; 2009 Mar; 31(3):527-41. PubMed ID: 19393843 [TBL] [Abstract][Full Text] [Related]
8. Opioid use by patients in an orthopedics spine clinic. Mahowald ML; Singh JA; Majeski P Arthritis Rheum; 2005 Jan; 52(1):312-21. PubMed ID: 15641058 [TBL] [Abstract][Full Text] [Related]
9. Switching from high doses of pure μ-opioid agonists to transdermal buprenorphine in patients with cancer: a feasibility study. Lundorff L; Sjøgren P; Hansen OB; Jonsson T; Nielsen PR; Christrup L J Opioid Manag; 2013; 9(4):255-62. PubMed ID: 24353018 [TBL] [Abstract][Full Text] [Related]
10. When opioids fail in chronic pain management: the role for buprenorphine and hospitalization. Berland DW; Malinoff HL; Weiner MA; Przybylski R Am J Ther; 2013; 20(4):316-21. PubMed ID: 23584313 [TBL] [Abstract][Full Text] [Related]
11. Opioid agonist doses for oxycodone and morphine dependence: Findings from a retrospective case series. Nielsen S; Bruno R; Degenhardt L; Demirkol A; Lintzeris N Drug Alcohol Rev; 2017 May; 36(3):311-316. PubMed ID: 27273511 [TBL] [Abstract][Full Text] [Related]
12. A feasibility study of transdermal buprenorphine versus transdermal fentanyl in the long-term management of persistent non-cancer pain. Mitra F; Chowdhury S; Shelley M; Williams G Pain Med; 2013 Jan; 14(1):75-83. PubMed ID: 23320402 [TBL] [Abstract][Full Text] [Related]
13. Opioid rotation from high-dose morphine to transdermal buprenorphine (Transtec) in chronic pain patients. Freye E; Anderson-Hillemacher A; Ritzdorf I; Levy JV Pain Pract; 2007 Jun; 7(2):123-9. PubMed ID: 17559481 [TBL] [Abstract][Full Text] [Related]
14. Changes in the prescribed daily doses of transdermal fentanyl and transdermal buprenorphine during treatment of patients with cancer and noncancer pain in Germany: results of a retrospective cohort study. Sittl R; Nuijten M; Nautrup BP Clin Ther; 2005 Jul; 27(7):1022-31. PubMed ID: 16154481 [TBL] [Abstract][Full Text] [Related]
15. Low-dose 7-day transdermal buprenorphine in daily clinical practice - perceptions of elderly patients with moderate non-malignant chronic pain. Uberall MA; Müller-Schwefe GH Curr Med Res Opin; 2012 Oct; 28(10):1585-95. PubMed ID: 22978772 [TBL] [Abstract][Full Text] [Related]
16. Transdermal buprenorphine patches applied in a 4-day regimen versus a 3-day regimen: a single-site, Phase III, randomized, open-label, crossover comparison. Likar R; Lorenz V; Korak-Leiter M; Kager I; Sittl R Clin Ther; 2007 Aug; 29(8):1591-606. PubMed ID: 17919542 [TBL] [Abstract][Full Text] [Related]
17. Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study. Simpson DM; Messina J; Xie F; Hale M Clin Ther; 2007 Apr; 29(4):588-601. PubMed ID: 17617282 [TBL] [Abstract][Full Text] [Related]
18. Long-term management of chronic pain with transdermal buprenorphine: a multicenter, open-label, follow-up study in patients from three short-term clinical trials. Likar R; Kayser H; Sittl R Clin Ther; 2006 Jun; 28(6):943-52. PubMed ID: 16860176 [TBL] [Abstract][Full Text] [Related]
19. Buprenorphine for chronic pain. Calderon R; Copenhaver D J Pain Palliat Care Pharmacother; 2013 Dec; 27(4):402-5. PubMed ID: 24245573 [TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic and pharmacodynamic properties of buprenorphine after a single intravenous administration in healthy volunteers: a randomized, double-blind, placebo-controlled, crossover study. Escher M; Daali Y; Chabert J; Hopfgartner G; Dayer P; Desmeules J Clin Ther; 2007 Aug; 29(8):1620-31. PubMed ID: 17919544 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]